Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Express Scripts
Boehringer Ingelheim
Moodys

Last Updated: December 2, 2022

Vincristine sulfate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for vincristine sulfate and what is the scope of patent protection?

Vincristine sulfate is the generic ingredient in six branded drugs marketed by Acrotech, Lilly, Teva Parenteral, Bristol Myers Squibb, Abic, Abraxis Pharm, Fresenius Kabi Usa, Hospira, and Teva Pharms Usa, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for vincristine sulfate. Two suppliers are listed for this compound.

Summary for vincristine sulfate
Recent Clinical Trials for vincristine sulfate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical College of WisconsinPhase 1
University of Colorado, DenverPhase 1
Boston Children's HospitalPhase 1

See all vincristine sulfate clinical trials

Pharmacology for vincristine sulfate
Drug ClassVinca Alkaloid
Medical Subject Heading (MeSH) Categories for vincristine sulfate

US Patents and Regulatory Information for vincristine sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira VINCRISTINE SULFATE vincristine sulfate INJECTABLE;INJECTION 071560-001 Apr 11, 1988 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Teva Pharms Usa VINCRISTINE SULFATE PFS vincristine sulfate INJECTABLE;INJECTION 075493-001 Sep 1, 1999 AP RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Hospira VINCRISTINE SULFATE PFS vincristine sulfate INJECTABLE;INJECTION 071484-001 Apr 19, 1988 AP RX No Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for vincristine sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ONCOVIN vincristine sulfate INJECTABLE;INJECTION 014103-003 Mar 7, 1984 See Plans and Pricing See Plans and Pricing
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 See Plans and Pricing See Plans and Pricing
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Johnson and Johnson
Dow
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.